telmisartan has been researched along with cardiovascular agents in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Barnett, A | 1 |
| Baumhäkel, M; Böhm, M | 1 |
| Avezum, A; Dagenais, G; Dans, T; Dehghan, M; Gao, P; Mente, A; Probstfield, JL; Sleight, P; Teo, KK; Yusuf, S | 1 |
| Majumdar, A; Nirwane, A; Pawar, V | 1 |
| Cao, TT; Chen, HH; Guo, W; Lu, R; Shan, XL; Tian, J; Wang, SN; Xu, M; Zhang, C; Zhao, P; Zheng, JL | 1 |
| Li, TT; Zhang, CH | 1 |
| Beckman, JA; Bonaca, MP; Hess, C | 1 |
2 review(s) available for telmisartan and cardiovascular agents
| Article | Year |
|---|---|
Prevention of loss of renal function over time in patients with diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Agents; Diabetic Nephropathies; Enalapril; Glomerular Filtration Rate; Humans; Kidney; Kidney Failure, Chronic; Proteinuria; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan; Time Factors; Treatment Outcome | 2006 |
Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan; Treatment Outcome | 2009 |
1 trial(s) available for telmisartan and cardiovascular agents
| Article | Year |
|---|---|
Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries.
Topics: Aged; Benzimidazoles; Benzoates; Cardiovascular Agents; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; Diet; Double-Blind Method; Female; Follow-Up Studies; Humans; Internationality; Male; Middle Aged; Prospective Studies; Risk Factors; Risk Reduction Behavior; Secondary Prevention; Surveys and Questionnaires; Telmisartan | 2012 |
4 other study(ies) available for telmisartan and cardiovascular agents
| Article | Year |
|---|---|
Therapeutic interventions using a combination of Telmisartan and omega 3-fatty acids in sodium arsenite-induced vascular endothelial dysfunction in rats: modulation through ATP-sensitive K+ channels and eNOS.
Topics: Animals; Aorta, Thoracic; Arsenites; Benzimidazoles; Benzoates; Cardiovascular Agents; Cholesterol; Endothelium, Vascular; Fatty Acids, Omega-3; Glyburide; KATP Channels; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type III; Oxidative Stress; Rats, Wistar; Sodium Compounds; Telmisartan; Thiobarbituric Acid Reactive Substances; Triglycerides; Vascular Diseases; Vasodilation | 2015 |
Stachydrine hydrochloride alleviates pressure overload-induced heart failure and calcium mishandling on mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Arterial Pressure; Calcium Signaling; Calcium-Binding Proteins; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiovascular Agents; Cells, Cultured; Disease Models, Animal; Heart Failure; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Phosphorylation; Proline; Rats; Rats, Sprague-Dawley; Ryanodine Receptor Calcium Release Channel; Sarcomeres; Sarcoplasmic Reticulum; Telmisartan; Ventricular Function, Left | 2020 |
A Common Electrocardiogram Demonstrating an Uncommon Cause.
Topics: Aorta, Thoracic; Aortic Diseases; Cardiovascular Agents; Chest Pain; Computed Tomography Angiography; Conservative Treatment; Coronary Angiography; Diagnosis, Differential; Electrocardiography; Fibrin Fibrinogen Degradation Products; Hematoma; Humans; Male; Middle Aged; Nitroglycerin; Telmisartan; Treatment Outcome | 2021 |
Telmisartan and Walking Performance in Peripheral Artery Disease.
Topics: Cardiovascular Agents; Humans; Peripheral Arterial Disease; Telmisartan; Walking | 2022 |